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Effects of Antihypertensive Drugs on Peritoneal Function in Human and Experimental Animals
Koji Tomori (Department of Nephrology, Saitama Medical School, Moroyama, Iruma-gun, Saitama 350-0495, 
JAPAN )
Antihypertensive therapy for the patients receiving continuous ambulatory peritoneal dialysis (CAPD) has been 
carried out without any guideline or clear results of large scale study. To investigate the effects of antihypertensive 
agents on peritoneal function, animal experiment and clinical obser vation were carried out. ＜Study1＞
Renovascular hypertension in dogs was induced with silver clips on both renal arteries that created 90% occlusion. 
After confirmation of elevation of blood pressure, usually 20 days after operation, the abdomen was opened while 
the animals were under general anesthesia. Using a CCD camera, diameters of the small arteries of the peritoneum 
were measured after oral administration of placebo (n＝5); 8 mg of CS866, a selective angiotensin II type I receptor 
blocker (n＝5); 10 mg of temocapril, an angiotensin converting enzyme inhibitor (n＝5); or 10 mg of amlodipine, 
a calcium antagonist (n＝5). Blood pressure was decreased in dogs with CS866 and a similar decrease was 
observed with the use of other drugs. The diameter of the small vessels was increased in dogs with CS866 and 
temocapril, respectively, compared with the calcium antagonist. ＜Study2＞ The effects of valsartan, on blood 
pressure, dialysate volume, and residual renal and peritoneal function in 36 CAPD patients  before and 3 months 
after oral administration valsartan 40 -80 mg daily were investigated comparing with amlodipine. Blood pressure 
was decreased significantly. Drain volume in peritoneal dialysis and a weekly peritoneal creatinine clearance was 
significantly increased. No significant changes in serum creatinine and hemoglobin were observed in both groups. 
In conclusion, these data clearly demonstrated that the blockade of the renin - angiotensin system produces an 
increase in solute clearance in hypertensive dogs with mild renal insufficiency. These data indicate that such 
blockade may be applicable as therapy for hypertensive patients on CAPD.  
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 緒　言
　持続携行式腹膜透析（Continuous Ambulatory 






























































































検討した． AQP-1プライマー配列は sense primer 
CTTCGTCTTCATCAGCATCG, anti-sense primer 
TGAGCACAACTGATGTGACC, AQP-4のプライマー
配列は sense primer ATGGTGGCTTTCAAAGGCGT，





















































Fig. 1. Effects of temocapril, an angiotensin converting enzyme (ACE) inhibitor, CS866, a 
selective angiotensin type 1 receptor blocker (ARB), amlodipine, a calcium antagonist on 
blood pressure and heart rate in dogs with renovascular hypertension. ** means p＜0.01 
compared to the control group.
Fig. 2.  Effects of antihypertensive drugs on the diameter of 
the vessels. Either temocapril or CS866 produced a significant 
vasodilator effect on the vessels. ** means p＜0.01 compared 
to the control group. 
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した．対象患者 36名を無作為に 2群に分け，一群に



















































高となり，その後 12週目まで 850 ml/day以上を維持
した．一方アムロジピン群における透析除水量に有意
な増加は認めず（開始時 760±18 ml/day，4週目 782±12 
Fig. 3. Effects of antihypertensive drugs on gene expression of aquaporin -1 and - 4 of the peritoneum. Both 
temocapril and CS866 significantly reduced aquaporin -1 and - 4 gene expression, but amlodipine induced a 





において 56.2±3.1 L/weekから 4週目より増加しは
じめ，その状態は 12週目まで維持された（79.4±2.8 
L/week）．一方アムロジピン群では経過中に大きな変化




















Fig. 4. Serial changes in systolic blood pressure over 12 
weeks after the treatment with an angiotensin receptor 
blocker (ARB), valsar tan (open circle), or a calcium 
antagonist, amlodipine (closed circle) in patients undergoing 
CAPD. Systolic blood pressure of both groups gradually 
decreased, but there was no significant difference between 
two groups. 
Fig. 5. Serial changes in diastolic blood pressure over 12 
weeks after the treatment with an angiotensin receptor 
blocker (ARB), valsar tan (open circle), or a calcium 
antagonist, amlodipine (closed circle) in patients undergoing 
CAPD. Diastolic blood pressure of both groups gradually 
decreased, but there was no significant difference between 
two groups.
Fig. 6. Serial changes in drain volume in peritoneal dialysis 
after the treatment with an angiotensin receptor blocker 
(ARB), valsartan (open column), or a calcium antagonist, 
amlodipine (closed column) in patients undergoing CAPD. 
Drain volume in valsartan group gradually increased, but 
there were significant dif ferences between two groups at 
week 4, 8, and 12. * means p＜0.05 compared with amlodipine 
group.
Fig. 7. Serial changes in peritoneal clearance in peritoneal 
dialysis after the treatment with an angiotensin receptor 
blocker (ARB), valsar tan (open column), or a calcium 
antagonist, amlodipine (closed column) in patients undergoing 
CAPD. Peritoneal clearance in valsartan group gradually 
increased, but there were significant differences between two 


































































報告している 23)．これらの Solute clearanceが増加した
ことは，血管拡張によっているのか，あるいは狭窄し
Fig. 9. Serial changes in serum creatinine in peritoneal 
dialysis after the treatment with an angiotensin receptor 
blocker (ARB), valsar tan (open column), or a calcium 
antagonist ,  amlodipine (closed column) in patients 
undergoing CAPD. Serum creatinine did not change in both 
groups during study period. There is no significant difference 
between two groups throughout the study.
Fig. 8. Serial changes in residual renal function in peritoneal 
dialysis after the treatment with an angiotensin receptor 
blocker (ARB), valsar tan (open column), or a calcium 
antagonist, amlodipine (closed column) in patients undergoing 
CAPD. Residual renal function did not change in both groups 
during study period. There is no significant dif ference 


































































ます．この研究の一部は 23rd Annual Conference on 
Peritoneal Dialysis（Seattle, USA 2003）で発表された．
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